Medical technology company Stryker has announced the launch of its latest product in the monitor/defibrillator space, the LIFEPAK 35 monitor/defibrillator.
The new device is designed to support life-saving teams by providing real-time access to critical patient information. It is built on an intuitive, modern platform to help advance patient care.
The LIFEPAK 35 is a connected solution that offers a slim, light, and ergonomic design, featuring a large intuitive touchscreen.
Stryker said the LIFEPAK 35 is built to deliver a customisable clinical experience for healthcare professionals, with trend monitoring capabilities to guide caregiver decisions.
The new monitor/defibrillator is designed with the modern healthcare professional in mind, offering advanced technology on an intuitive platform, stated the company.
The LIFEPAK 35’s connected capabilities for patient data are configurable, supporting advanced patient care through informed decision-making.
How well do you really know your competitors?
Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.
Thank you!
Your download email will arrive shortly
Not ready to buy yet? Download a free sample
We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form
By GlobalDataStryker Emergency Care business vice-president and general manager Anne Mullally said: “After more than ten years of research, coupled with feedback from hundreds of our customers around the globe, we’re excited to offer first responders and essential healthcare professionals an innovative monitor/defibrillator in a familiar, trusted platform.
“By enabling more efficient workflow and providing clinical advancements with LIFEPAK 35, we are proud to support the challenges these providers face in our communities.”
This week, Stryker signed an agreement to acquire all issued and outstanding shares of Artelon.
The acquisition aims to bolster Stryker’s offerings in the soft tissue fixation segment.